Therapeutic equivalence of alendronate 70 mg onceweekly and alendronate 10 mg daily in the treatment of osteoporosis
- 1 February 2000
- journal article
- research article
- Published by Springer Nature in Aging Clinical and Experimental Research
- Vol. 12 (1) , 1-12
- https://doi.org/10.1007/bf03339822
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT StudyOsteoporosis International, 1999
- Pharmacokinetics of AlendronateClinical Pharmacokinetics, 1999
- Effect of Alendronate on Risk of Fracture in Women With Low Bone Density but Without Vertebral FracturesResults From the Fracture Intervention TrialJAMA, 1998
- Prevention of Bone Loss with Alendronate in Postmenopausal Women under 60 Years of AgeNew England Journal of Medicine, 1998
- Alendronate Prevents Postmenopausal Bone Loss in Women without Osteoporosis: A Double-Blind, Randomized, Controlled TrialAnnals of Internal Medicine, 1998
- Elimination and Biochemical Responses to Intravenous Alendronate in Postmenopausal OsteoporosisJournal of Bone and Mineral Research, 1997
- Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fracturesThe Lancet, 1996
- Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal OsteoporosisNew England Journal of Medicine, 1995
- The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates.Journal of Clinical Investigation, 1993
- The bisphosphonate alendronate (MK-217) inhibits bone loss due to ovariectomy in ratsJournal of Bone and Mineral Research, 1991